
    
      This study will include a 1-week screening period; an up to 12-week metformin titration/dose
      stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A
      and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14
      days after the last dose of study medication.
    
  